Company intelligence / Profile preview

Encodia

San Diego, California, United Statesencodia.com ↗

Ownership: Private
Employees: ~125
Development stage: Preclinical

Overview

Encodia’s ProteoCode™ platform enables scalable, high-throughput protein sequencing by converting peptide sequences into DNA barcodes readable by standard NGS sequencers. The company has raised significant funding to accelerate the productization of this technology for life science research and future clinical applications. No published clinical results as the focus remains on enabling discovery and multiomic integration at scale.

Therapeutic areas: Other
Modalities: Proteomics (protein sequencing)NGS-based protein analysis (Next Generation Sequencing)
Industry: Protein Biomarker Diagnostics

Partnerships

No specific major pharmaceutical or biotech partnerships publicly disclosed as of latest available information.

Beyond the preview

Go deeper on Encodia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Encodia.

Explore the full profile